Literature DB >> 10051062

Sampling technique from central venous catheters proves critical for pharmacokinetic studies.

A D Huitema1, M Holtkamp, M M Tibben, S Rodenhuis, J H Beijnen.   

Abstract

Double-lumen central venous access (CVA) catheters are occasionally used in pharmacokinetic studies for drug administration and blood sampling. The samples are often collected by the nursing staff and thus the investigator may not be aware of the specific sampling technique used. We present an example of the dramatic effect that an incorrect sampling technique from double-lumen CVA catheters can have on pharmacokinetic outcomes. Using a double-lumen Hickman catheter (PolyCath Central Venous Catheter; Strato Medical Corporation/Infusaid Inc., Manchester, GA, U.S.A.), sampling during the infusion can be performed when the infusion is connected to the lumen with the end most downstream and blood is collected from the proximal opening. With a normal double-lumen catheter, sampling can only be performed by briefly interrupting the infusion or after the infusion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051062     DOI: 10.1097/00007691-199902000-00016

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Authors:  A D Huitema; R A Mathôt; M M Tibben; J H Schellens; S Rodenhuis; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

2.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer.

Authors:  Jeffrey M Skolnik; Alena Y Zhang; Jeffrey S Barrett; Peter C Adamson
Journal:  Ther Drug Monit       Date:  2010-12       Impact factor: 3.681

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.